Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | ACE | P12821 | 3/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.48 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.48 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.48 |
| ▸ | PRKX | P51817 | 1/20 | 0.48 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.48 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28653631 | 1.00 | SIGMAR1 (0.51) | SIGMAR1MMEMAPK1ACEROCK2 | |
| SCHEMBL28653629 | 1.00 | SIGMAR1 (0.51) | SIGMAR1MMEMAPK1ACEROCK2 | |
| SCHEMBL7041284 | 0.91 | SIGMAR1 (0.55) | SIGMAR1MAPK1ROCK2ROCK1RPS6KA5 | |
| SCHEMBL23023068 | 0.91 | SIGMAR1 (0.55) | SIGMAR1MAPK1ROCK2ROCK1RPS6KA5 | |
| SCHEMBL1823141 | 0.91 | SIGMAR1 (0.55) | SIGMAR1MAPK1ROCK2ROCK1RPS6KA5 | |
| SCHEMBL6487410 | 0.87 | CNR1 (0.56) | SIGMAR1MAPK1CYP3A4KDM4EMEN1 | |
| SCHEMBL6487403 | 0.87 | CNR1 (0.56) | SIGMAR1MAPK1CYP3A4KDM4EMEN1 | |
| SCHEMBL6540788 | 0.85 | SIGMAR1 (0.46) | SIGMAR1MAPK1CYP3A4KDM4EMEN1 | |
| SCHEMBL6540775 | 0.85 | SIGMAR1 (0.46) | SIGMAR1MAPK1CYP3A4KDM4EMEN1 | |
| SCHEMBL10877160 | 0.85 | SMN1; SMN2 (0.51) | SIGMAR1MAPK1HTTRAB9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023206874-A1 | SACUBITRIL INTERMEDIATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 凯特立斯（深圳）科技有限公司 | 2023-11-02 | — | — | WO | disclosed |
| US-10774036-B2 | Process for early sacubitril intermediates | NOVARTIS AG (CH) | 2020-09-15 | — | — | US | disclosed |
| US-20190256454-A1 | NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES | NOVARTIS PHARMA AG (CH) | 2019-08-22 | — | — | US | disclosed |
| US-10183909-B2 | Process for preparation of N-Boc biphenyl alaninol | CHIRAL QUEST (SUZHOU) CO., LTD. (CN) | 2019-01-22 | — | — | US | disclosed |
| US-9139515-B2 | Synthesis of R-biphenylalaninol | DPX HOLDINGS B.V. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139515-B2 | Synthesis of R-biphenylalaninol | DPX HOLDINGS B.V. (US) | 2015-09-22 | — | — | US | disclosed |
| WO-2015024991-A1 | SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES | DPX HOLDINGS B.V. (NL) | 2015-02-26 | — | — | WO | disclosed |
| US-20140296559-A1 | SYNTHESIS OF R-BIPHENYLALANINOL | DSM FINE CHEMICALS AUSTRIA NFG. GMBH & CO KG (AT) | 2014-10-02 | — | — | US | disclosed |
| US-20140296559-A1 | SYNTHESIS OF R-BIPHENYLALANINOL | DSM FINE CHEMICALS AUSTRIA NFG. GMBH & CO KG (AT) | 2014-10-02 | — | — | US | disclosed |
| WO-2013026773-A1 | SYNTHESIS OF R-BIPHENYLALANINOL | DSM IP ASSETS B.V. (NL) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774036-B2 | Process for early sacubitril intermediates | MME, ACE, DNPEP | SIGMAR1 751/4885MME 1/4885MAPK1 3057/4885 |
| US-10183909-B2 | Process for preparation of N-Boc biphenyl alaninol | RABL6, PF4, SPIN4 | SIGMAR1 2413/4885MME 4359/4885MAPK1 4440/4885 |
| US-20140296559-A1 | SYNTHESIS OF R-BIPHENYLALANINOL | CYP2B6, CYP2A6, CYP2D6 | SIGMAR1 2844/4885MME 506/4885MAPK1 4276/4885 |
| US-20190256454-A1 | NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES | MME, ACE, DNPEP | SIGMAR1 538/4885MME 1/4885MAPK1 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.